Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults. The company also markets Epicel, a cultured epidermal autograft used to cover and help treat severe burns and other extensive skin wounds. In addition, Vericel commercializes NexoBrid in the United States, a topical enzymatic treatment designed to remove nonviable tissue from deep thermal burns.

Vericel is headquartered in Cambridge, Massachusetts, and primarily serves the United States through relationships with orthopedic surgeons, burn centers and other specialized health-care providers. The company traces its operations to the cell-therapy businesses acquired from Genzyme in 2014 by Aastrom Biosciences, which subsequently adopted the Vericel name. Its products are developed for specialized clinical settings where regenerative medicine and advanced wound-care technologies may provide alternatives to conventional treatment approaches.

Key Stats

• Today's Range: $39.97 to $41.03
• 50-Day Range: $37.87 to $44.73
• 52-Week Range: $28.95 to $49.32
• Volume: 475,254 shs
• Average Volume: 532,356 shs
• Market Capitalization: $2.08 billion
• P/E Ratio: 86.34
• Dividend Yield: N/A
• Price Target: $57.20
• Consensus Rating: Moderate Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 84% of companies evaluated by MarketBeat, and ranked 84th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vericel has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Vericel has a consensus price target of $57.20, representing about 41.0% upside from its current price of $40.58.

Amount of Analyst Coverage

Vericel has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 55.56%

Earnings Growth

Earnings for Vericel are expected to grow by 55.56% in the coming year, from $0.54 to $0.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 86.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 86.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 177.10.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.00% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.64.

Change versus previous month

Short interest in Vericel has recently decreased by 5.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.56

News Sentiment

Vericel has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vericel this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for VCEL on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Vericel to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $220,050.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Vericel is held by insiders.

Percentage Held by Institutions

Vericel has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 398
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vericel: $57.20
• High Price Target: $70.00
• Low Price Target: $46.00
• Potential Upside/Downside: +41.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.47
• Trailing P/E Ratio: 86.34
• Forward P/E Ratio: 75.15
• P/E Growth: N/A
• Net Income: $16.52 million
• Net Margins: 7.91%
• Pretax Margin: 8.19%
• Return on Equity: 6.91%
• Return on Assets: 5.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 4.69

Sales & Book Value

• Annual Sales: $276.26 million
• Price / Sales: 7.52
• Cash Flow: $0.56 per share
• Price / Cash Flow: 72.67
• Book Value: $7.01 per share
• Price / Book: 5.79

Miscellaneous

• Outstanding Shares: 51,210,000
• Free Float: 47,315,000
• Market Cap: $2.08 billion
• Optionable: Optionable
• Beta: 1.02